The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Remisar     2-amino-5-bromo-6-phenyl-1H- pyrimidin-4-one

Synonyms: Bropirimina, Bropirimine, ABPP, Bropiriminum, SureCN4058, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Bropirimine


High impact information on Bropirimine


Chemical compound and disease context of Bropirimine


Biological context of Bropirimine


Anatomical context of Bropirimine


Associations of Bropirimine with other chemical compounds


Gene context of Bropirimine


Analytical, diagnostic and therapeutic context of Bropirimine


  1. Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine. Borden, E.C., Sidky, Y.A., Ertürk, E., Wierenga, W., Bryan, G.T. Cancer Res. (1990) [Pubmed]
  2. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs. Li, L.H., DeKoning, T.F., Wallace, T.L. Cancer Res. (1987) [Pubmed]
  3. Phase 1 trial of oral bropirimine in superficial bladder cancer. Sarosdy, M.F., Lamm, D.L., Williams, R.D., Moon, T.D., Flanigan, R.C., Crawford, E.D., Wilks, N.E., Earhart, R.H., Merritt, J.A. J. Urol. (1992) [Pubmed]
  4. In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate cancers. Sarosdy, M.F., Higdon, A.L., Demoor, C.A. J. Urol. (1996) [Pubmed]
  5. Treatment of carcinoma in situ of the urinary bladder with bropirimine. Witjes, J.A. Eur. Urol. (1997) [Pubmed]
  6. Cytokine induction in mice by the immunomodulator imiquimod. Reiter, M.J., Testerman, T.L., Miller, R.L., Weeks, C.E., Tomai, M.A. J. Leukoc. Biol. (1994) [Pubmed]
  7. Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine. Smee, D.F., Morris, J.L., Leonhardt, J.A., Mead, J.R., Holy, A., Sidwell, R.W. Antimicrob. Agents Chemother. (1992) [Pubmed]
  8. Biological response modifiers for the treatment of superficial bladder tumors. Zlotta, A.R., Schulman, C.C. Eur. Urol. (2000) [Pubmed]
  9. Effects of an interferon inducer bropirimine on bleomycin-induced lung fibrosis in hamsters. Zia, S., Hyde, D.M., Giri, S.N. Pharmacol. Toxicol. (1992) [Pubmed]
  10. A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study. Sarosdy, M.F., Tangen, C.M., Weiss, G.R., Nestok, B.R., Benson, M.C., Schellhammer, P.F., Sagalowsky, A.I., Wood, D.P., Crawford, E.D. Urol. Oncol. (2005) [Pubmed]
  11. Reversal of bropirimine developmental toxicity with progesterone. Black, D.L., Marks, T.A., Branstetter, D.G., Kirton, K.T. Toxicol. Appl. Pharmacol. (1991) [Pubmed]
  12. Assay of bropirimine in rat plasma by means of robotic solid-phase extraction and high-performance liquid chromatography. Hsu, C.Y., Walters, R.R. Journal of chromatography. A. (1997) [Pubmed]
  13. Comparative mutagenicity testing of bropirimine, 2. Further characterization and mechanistic investigation of clastogenesis. Petry, T.W., Aaron, C.S., Ulrich, R.G., Donarski, W.J., Thilagar, A., Kumaroo, P.V. Mutat. Res. (1991) [Pubmed]
  14. Comparative mutagenicity testing of bropirimine, 3. Bropirimine does not induce cytogenetic damage in vivo in the rat but does produce micronuclei in the mouse. Aaron, C.S., Petry, T.W., Branstetter, D.G., Wickrema-Sinha, A.J., Yu, R., Sorg, R., Thilagar, A., Kumaroo, P.V., Sams, J.P., Thornburg, B.A. Mutat. Res. (1991) [Pubmed]
  15. Human biotransformation of bropirimine. Characterization of the major bropirimine oxidative metabolites formed in vitro. Wynalda, M.A., Hauer, M.J., Wienkers, L.C. Drug Metab. Dispos. (1998) [Pubmed]
  16. Comparative mutagenicity testing of bropirimine, 1. Induction of chromosome aberrations in CHO cells is not reflected in induction of mutation at the TK locus of L5178Y cells. Aaron, C.S., Petry, T.W., Thilagar, A., Kumaroo, P.V., Kirby, P. Mutat. Res. (1991) [Pubmed]
  17. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin. Sarosdy, M.F., Manyak, M.J., Sagalowsky, A.I., Belldegrun, A., Benson, M.C., Bihrle, W., Carroll, P.R., Ellis, W.J., Hudson, M.A., Sharkey, F.E. Urology (1998) [Pubmed]
  18. Bropirimine immunotherapy of upper urinary tract carcinoma in situ. Sarosdy, M.F., Pisters, L.L., Carroll, P.R., Benson, M.C., Moon, T.D., Lamm, D.L., Hudson, M.A., Lerner, S.P., Koch, M.O., Schellhammer, P.F. Urology (1996) [Pubmed]
  19. Pyrimidinone (bropirimine) mediated alteration of T lymphocyte subsets during murine cytomegalovirus infection. Brideau, R.J., Nicholas, J.A. Clin. Exp. Immunol. (1987) [Pubmed]
  20. Characterization of bropirimine O-glucuronidation in human liver microsomes. Wynalda, M.A., Wynalda, K.M., Amore, B.M., Fagerness, P.E., Wienkers, L.C. Xenobiotica (2003) [Pubmed]
  21. Small intestinal absorption of bropirimine in rats and effect of bile salt on the absorption. Emori, H., Yokohama, S., Nishihata, T. J. Pharm. Pharmacol. (1995) [Pubmed]
  22. Lack of interaction between bropirimine and 5-fluorouracil on human dihydropyrimidine dehydrogenase. Yamazaki, S., Hayashi, M., Toth, L.N., Ozawa, N. Xenobiotica (2001) [Pubmed]
  23. Prevention of human recombinant interleukin-1 beta (rhIL-1 beta) embryolethality with progesterone or indomethacin. Marks, T.A., Tracy, D.E. Am. J. Reprod. Immunol. (1995) [Pubmed]
  24. In vitro antitumor activity of bropirimine against urinary bladder tumor cells. Tei, Y., Matsuyama, H., Wada, T., Kurisu, H., Tahara, M., Naito, K. Anticancer Res. (2002) [Pubmed]
  25. Pharmacology of the biological response modifier bropirimine (PNU-54461) on experimental autoimmune encephalomyelitis (EAE) in mice. Vroegop, S.M., Chapman, D.L., Galinet, L.A., Decker, D.E., Ready, K.A., Brideau, R.J., Dunn, C.J., Buxser, S.E. Int. J. Immunopharmacol. (1999) [Pubmed]
  26. Antitumor effects of oral administration of an interferon-inducing pyrimidinone, Bropirimine, on murine renal-cell carcinoma. Fujioka, T., Ishikura, K., Hasegawa, M., Ogyu, K., Matsushita, Y., Sato, M., Sato, F., Aoki, H., Kubo, T. Cancer Chemother. Pharmacol. (1995) [Pubmed]
WikiGenes - Universities